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Abstract
Background: There is clear evidence that nutrition and lifestyle can modify colorectal cancer risk. However, it is not
clear if those factors can affect colorectal cancer treatment, recurrence, survival and quality of life. This paper
describes the background and design of the “COlorectal cancer: Longitudinal, Observational study on Nutritional
and lifestyle factors that may influence colorectal tumour recurrence, survival and quality of life” – COLON – study.
The main aim of this study is to assess associations of diet and other lifestyle factors, with colorectal cancer
recurrence, survival and quality of life. We extensively investigate diet and lifestyle of colorectal cancer patients at
diagnosis and during the following years; this design paper focusses on the initial exposures of interest: diet and
dietary supplement use, body composition, nutrient status (e.g. vitamin D), and composition of the gut microbiota.
Methods/Design: The COLON study is a multi-centre prospective cohort study among at least 1,000 incident
colorectal cancer patients recruited from 11 hospitals in the Netherlands. Patients with colorectal cancer are
invited upon diagnosis. Upon recruitment, after 6 months, 2 years and 5 years, patients fill out food-frequency
questionnaires; questionnaires about dietary supplement use, physical activity, weight, height, and quality of life;
and donate blood samples. Diagnostic CT-scans are collected to assess cross-sectional areas of skeletal muscle,
subcutaneous fat, visceral fat and intermuscular fat, and to assess muscle attenuation. Blood samples are biobanked to
facilitate future analyse of biomarkers, nutrients, DNA etc. Analysis of serum 25-hydroxy vitamin D levels, and
analysis of metabolomic profiles are scheduled. A subgroup of patients with colon cancer is asked to provide
faecal samples before and at several time points after colon resection to study changes in gut microbiota during
treatment. For all patients, information on vital status is retrieved by linkage with national registries. Information
on clinical characteristics is gathered from linkage with the Netherlands Cancer Registry and with hospital databases.
Hazards ratios will be calculated for dietary and lifestyle factors at diagnosis in relation to recurrence and survival.
Repeated measures analyses will be performed to assess changes over time in dietary and other factors in relation
to recurrence and survival.
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Background
Colorectal cancer is the third most common type of
cancer worldwide [1]. Lifestyle and nutritional factors
influence colorectal cancer risk. High consumption of
red and processed meat and alcoholic beverages and
low consumption of foods containing dietary fibre
convincingly increase the risk of colorectal cancer.
Body fatness – especially abdominal fatness-, and
adult attained height increase the risk of colorectal
cancer, while physical activity protects against colo-
rectal cancer [2,3].
In contrast to the extensive knowledge on the role of
nutrition and lifestyle in the prevention of colorectal
cancer, much less is known about the role of diet and
lifestyle during and after treatment of colorectal cancer.
Few prospective studies reported on factors that were
associated with colorectal cancer recurrence and sur-
vival, while those studies were often hampered by the
fact that dietary assessment was retrospective, that
patient groups were small and heterogeneous, or that
other prognostic factors were not taken into account [4].
Evidence-based lifestyle recommendations are necessary
for the increasing number of colorectal cancer survi-
vors, since these survivors may show a major interest in
adjusting their usual habits [5-7]. The aim of the current
study is to further explore the association between diet
and other lifestyle factors in colorectal cancer prog-
nosis, survival and quality of life, with special emphasis
for the role of diet and dietary supplement use, body
composition, nutrient status, and composition of the
gut microbiota.
Few prospective studies assessed the association between
diet and dietary supplement use and colorectal cancer
prognosis and survival. An observational study within a
randomized controlled chemotherapy trial (n = 1,009
stage III colorectal cancer patients) [8], showed that
colorectal cancer patients who scored high on a diet
that could be described as a Western diet, with high
intakes of meat, fat, refined grains, and desserts, had a 3
times higher risk of cancer recurrence or death (HR 3.25
(2.04-5.19)) than persons who scored low on such a pat-
tern. Conversely, a prudent pattern, high in vegetables,
fruits, poultry, and fish, was not associated with colo-
rectal cancer outcomes in that study. There are only few
additional publications on diet and colorectal cancer
outcomes [4]. It is unclear if the use of dietary supple-
ments by colorectal cancer patients affects colorectal
cancer recurrence and survival. Dietary supplement
use among patients has been assessed in several –
mainly US – studies and is estimated to be as high as
60-80% [9]. An observational study, again within a ran-
domized controlled chemotherapy trial (n = 1,038 stage
III patients) showed that multivitamin use during and after
adjuvant chemotherapy was not significantly associated
with outcomes in patients with stage III colon cancer [10].
It has been hypothesized that folic acid supplementation,
may be involved in progression of established neoplasms
[11]. This stresses the need to further address the role of
dietary supplement use during and after colorectal cancer
treatment.
Some data suggest that colorectal cancer patients who
are obese or underweight may experience higher mor-
tality rates than normal and overweight patients [4,12-15],
however study results are not consistent. Underweight,
overweight and obesity are usually only assessed by
measuring the body mass index (BMI) [16-18], while
BMI is not a valid measure for fat distribution or body
composition [19]. Muscle depletion – assessed from
diagnostic computed tomography (CT)-scans - has been
associated with worse survival in a mixed groups of
cancer patients (n = 1,400), independently of BMI [20].
Moreover, among obese patients, those who are sarco-
penic – i.e. those with severe muscle depletion- appear to
have worse survival than patients who are not-sarcopenic
[21]. This warrants further study on the association
between muscle mass, fat mass and survival among
cancer patients. In addition, fat distribution of abdom-
inal fat is an area that requires further investigation.
Abdominal fat is mainly divided into two depots: sub-
cutaneous and intra-abdominal or visceral fat. Visceral fat
accumulation has been associated with increased inci-
dence of colorectal cancer [5]; its association with re-
currence of colorectal cancer has only sparsely been
studied in small studies with short follow-up [22-25].
Nevertheless, those studies suggest that increased visceral
fat areas, or an increased visceral fat vs subcutaneous
fat ratio may increase the risk of recurrence. Visceral
adiposity may also unfavourably affect colorectal cancer
survival, but again this has only been studied in small
populations (50–200 patients) with short follow-up and
mostly in patients with metastatic disease [22-24,26];
results were therefore not conclusive. Concluding, the
associations of body composition and fat distribution with
recurrence and survival of colorectal cancer patients are
promising areas of investigation.
Nutrient status at diagnosis as well as during treat-
ment may also affect recurrence and survival. For instance,
the role of vitamin D in colorectal cancer prevention
and survival has gained much interest in recent years.
A recent meta-analysis suggested that higher 25(OH)D
levels (>75 nmol/L) were associated with significantly
reduced mortality in patients with colorectal cancer [27].
Results should be interpreted with caution, as the
assessment of 25(OH)D levels differed between the
individual studies of the meta-analysis (pre vs post-
diagnostic). Moreover, most studies only have one meas-
urement of vitamin D levels, while cancer treatment and
stage of disease may have a large impact on vitamin D
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status. Thus, cohort studies with repeated measurement
of vitamin D levels are urgently needed.
Many colorectal cancer patients treated with chemo-
therapy suffer from mucositis and gastrointestinal com-
plaints, such as severe diarrhoea, nausea and vomiting
[28,29]. Knowledge on the role of the gut microbiota - a
major compartment of the gastrointestinal tract- in
human health has emerged in the past years [30]. Yet,
the gut microbiota has been relatively ignored in stud-
ies focusing on the pathophysiology and side-effects of
cancer therapies [31]. There is some evidence that
chemotherapy induces a large decline in the diversity
of the gut microbiota [32,33]. To what extent colorec-
tal cancer patients receiving chemotherapy experience
similar declines in diversity and whether diet and life-
style affect recovery of the gut microbiota during and
after chemotherapy is largely unknown.
In this study, we will assess associations of diet and
other lifestyle factors, with colorectal cancer recurrence
and survival and with quality of life. We comprehen-
sively investigate diet and lifestyle of colorectal cancer
patients at diagnosis and during the following years. This
design paper focusses on the four initial topics of interest
in this prospective cohort study: diet and dietary supple-
ment use, body composition, nutrient status (e.g. vitamin
D), and composition of the gut microbiota.
Methods/design
The “Colorectal cancer: Longitudinal, Observational study
on Nutritional and lifestyle factors that influence colo-
rectal tumour recurrence, survival and quality of life” –
COLON - study is a prospective observational cohort
study that aims to include at least 1,000 colorectal can-
cer patients from regional and academic hospitals in the
Netherlands over a period of ~5 years. Ethical approval for
the study was granted by the Committee on Research
involving Human Subjects, region Arnhem-Nijmegen
(Commissie Mensgebonden Onderzoek – CMO, region
Arnhem Nijmegen).
Recruitment
Men and women of all ages, who were newly diagnosed
with colorectal cancer (ICD codes C18-20) in any stage
of the disease in one of the 11 participating hospitals,
are eligible for the study. Non-Dutch speaking patients, or
patients with a history of colorectal cancer or (partial)
bowel resection, chronic inflammatory bowel disease,
hereditary colorectal cancer syndromes (Lynch syndrome,
FAP, Peutz-Jegher), dementia or another mental condition
that makes it impossible to fill out questionnaires
correctly, will be excluded from the study. Recruitment
is conducted in close cooperation with staff of the
oncology, gastroenterology and/or internal medicine
departments of the participating hospitals. Recruitment
procedures vary slightly per hospital. In general, eligible
patients receive an information leaflet about the COLON
study from their treating physician or from the nurse-
practitioner shortly after diagnosis during a routine
clinical visit. Patients can consult with their physician
or nurse-practitioner, with a member of the study team,
and/or with an independent physician if they have ques-
tions about the study. Patients who agree to participate
have to provide written informed consent.
Data collection
Patients are asked to fill out several questionnaires
upon recruitment (at diagnosis), at 6 months, 2 years
and 5 years after recruitment (Figure 1). In addition,
participants are asked to donate a blood sample at each
time point. Patients who are treated with chemotherapy,
are asked to additionally fill out questionnaires and to
donate an extra blood sample 1 year after recruitment.
At that point in time most of those patients will have
completed their treatment, while other patients will
have finished their treatment within 6 months. Patients are
asked for permission for collection of paraffin-embedded
tumor-material using the nationwide network and registry
of histo- and cytopathology in the Netherlands (PALGA).
Demographic and health characteristics
Demographic and health characteristics are assessed
with a self-administered lifestyle questionnaire containing
questions on demographics (education, ethnicity, living
situation, number of children), body weight and height,
history of body weight, smoking habits, history of medica-
tion (including use of aspirin and other NSAIDs), family
history of cancer, any changes that patients made to their
diet because of bowel complaints or other reasons, type of
(alternative) treatment, experienced side-effects of treat-
ment, comorbidities, and for women: menopausal status,
menstrual and reproductive history.
Dietary intake & dietary supplement use
Habitual dietary intake in the month preceding diagnosis
- and for the other time-points the preceding month -, is
assessed using a semi-quantitative food frequency ques-
tionnaire. This questionnaire was previously validated
[34,35], and slightly adapted to be able to distinguish
meat intake with respect to red, processed, and white
meat, and for dairy to be able to distinguish fermented
and unfermented dairy. For all items, frequencies per
day and standard portion sizes will multiplied to obtain
intake in grams per day. Energy intake and nutrient
intakes will be calculated using the Dutch food com-
position table [36]. Additionally, the food frequency
questionnaire contains questions on the use of organic
foods, i.e. the type of organic foods and the frequency
of use.
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Dietary supplement is assessed using a self-administered
dietary supplement questionnaire developed by the
Division of Human Nutrition of Wageningen Univer-
sity, the Netherlands. The dietary supplement ques-
tionnaire contains questions on use of multivitamin/
minerals supplements and other mixtures not classified
as multivitamins/minerals (e.g. vitamin B-complex, anti-
oxidant mixtures, combination of vitamin A/D, mixture
of calcium/magnesium/zinc, other mixtures), and sup-
plemental vitamin A, folic acid, vitamin B12, vitamin C,
vitamin D, vitamin E, calcium, magnesium, zinc, iron,
selenium, chrome, fish oil, and herbal and specialty sup-
plements, and on the dosage and frequency of intake.
Upon recruitment, participants are asked whether they
used any dietary supplement during the year before
colorectal cancer diagnosis. At the other time-points,
dietary supplement use in the period since the last ques-
tionnaire is enquired.
Body composition
Patients are asked to measure and report their waist and
hip circumference; instructions and a measuring device
are provided. In addition, CT-images are retrieved from
medical records of all participants for the assessment of
body composition. Diagnostic CT-images are available
from almost all colorectal cancer patients (~85-90%), as
Core of the COLON-study
Invitaon of incident 
colorectal cancer paents
newly diagnosed in one of 
the parcipang hospitals 
Informed consent 
Start of clinical treatment
- Blood collecon
- Quesonnaires
6 months aer diagnosis 
2 years aer diagnosis 
5 years aer diagnosis 
- Blood collecon
- Quesonnaires 
- Blood collecon
- Quesonnaires
- Blood collecon
- Quesonnaires 
- Medical chart review 
to assess treatment 
characteriscs
- Collecon of 
diagnosc CT-scan
Subgroup of colon
cancer paents: 
faecal sample 
collecon at 
diagnosis (i.e. before 
colon resecon), and 
6, 12 and 35 weeks 
aer resecon
- Check for vital status
- Linkage with cancer
registry
- Medical chart review 
to assess recurrence 
and treatment 
characteriscs
Subgroup of paents 
treated with chemo:
Addional blood 
collecon + 
quesonnaires at 1 
year aer diagnosis
Figure 1 Overview and design of the COLON study.
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they are used for diagnosis and staging of the disease.
From these CT-images, cross-sectional areas (cm2) of
skeletal muscle, subcutaneous fat, visceral fat and
inter-muscular fat will be quantified at the landmark
level of the third lumbar vertebra (L3) using Slice-O-
matic software (Tomovision, Canada). Cross-sectional
L3 adipose and muscle areas are linearly related to
total body adipose and muscle mass [37-39].
Physical activity
Self-reported physical activity is assessed using the Short
Questionnaire to ASsess Health-enhancing physical
activity (SQUASH) [40]. The general purpose of this
questionnaire is to assess habitual physical activity,
with a reference period of a normal week in the past
months. Participants are asked to report their average
time spend on the following pre-structured types of
activities: commuting activities, activity at work, house-
hold activities and leisure time activities (walking, bicyc-
ling, gardening, odd jobs and up to four sports). The
SQUASH consists of three main queries: days per week,
average time per day, and intensity. The recorded activity
will be converted into Metabolic Equivalent (MET)-scores
using the Compendium of Physical Activities [41].
Validation studies [40,42,43] showed that the SQUASH-
questionnaire is fairly reliable and reasonably valid in an
adult population and may be used to rank participants
based on their physical activity level and to categorize
them according to the Dutch physical activity guideline
(30 minutes or more of at least moderate intense phys-
ical activity for a minimum of 5 days per week).
Blood sample collection and analysis
Non-fasting blood samples are drawn from patients
upon recruitment and at all later time-points during a
regular clinical visit of the patient. The baseline blood
sample is preferably taken before surgery or start of
treatment. In case of neo-adjuvant radiation therapy, it
is not always possible to draw blood before the start of
treatment, and for those patients a blood sample is
collected before surgery. For each blood sample, haem-
atocrit is assessed immediately after blood draw at all
study sites. Blood samples are processed into serum (6
aliquots), plasma (5 aliquots), full blood (2 aliquots), and
buffy coat (2 aliquots) and stored in a biobank at −80°C.
All procedures are defined in a protocol in order to
ensure standardisation over study sites. Blood samples
are biobanked for later analysis of metabolites, bio-
markers, nutrients etc. Analysis of 25-hydroxy vitamin D
is already anticipated; in addition, metabolomics will be
performed. Both 25-hydroxy vitamin D2 and 25-hydroxy
vitamin D3 levels will be assessed in serum samples
using a liquid chromatography tandem mass spectrom-
etry method [44]. In a subset of the patients targeted
and untargeted metabolomic analysis will be performed
using the Biocrates AbsoluteIDQ p180 Kit for the tar-
geted approach and UPLC-ESI-qTOF for the untargeted
approach at the IARC, France.
Faecal sample collection and analysis
In order to assess whether cancer therapy affects compos-
ition and function of the gut microbiota in colon cancer
patients, faecal samples are collected from a subgroup of
patients with colon cancer who are diagnosed in one of
the participating hospitals (Hospital Gelderse Vallei, Ede).
Faecal samples are collected shortly after diagnosis (i.e.
before colon resection), and 6, 12 and 35 weeks after
resection. For patients who are treated with chemo-
therapy, this corresponds to sample collection before,
during and after chemotherapy. A phylogenetic micro-
array (the Human Intestinal Tract Chip; HITCHip) will
be used for a high-throughput characterisation of the
composition of the gut microbiota [45].
Clinical outcome measurements
Information on clinical factors are retrieved from linkage
with the Netherlands Cancer Registry and will include:
pathologic and clinical disease stage (TNM), date of
colorectal cancer incidence, location of the tumour,
morphology, degree of differentiation, number of lymph
nodes surgically sampled and number of positive lymph
nodes, type and date of surgery, surgical complications
(anastomotic leakage, abscess), tumour residue, type of
treatment (chemotherapy, radiotherapy, chemoradiation,
other) and date of start treatment, location of metastases
(ICD-code) and distance of tumour from anus (rectal
tumours only). Additional clinical data will be retrieved
from medical record abstraction. We are using stan-
dardized forms and methods to abstract the medical
records for all of the participants at regular intervals
during the cohort study. Medical variables include history
of gastro-intestinal disease, date and indication for
endoscopy at diagnosis, length of hospital stay after
primary surgery, body weight and height, size of the
tumour, length of surgically removed bowel, CEA level,
all treatment and follow-up care including data on
chemotherapy and radiation therapy, adenoma/carcin-
oma recurrence.
The main outcomes of this cohort are treatment com-
pletion rates, side-effects of treatment, disease outcomes
and quality of life. Disease outcomes are: colorectal
cancer recurrence, colorectal adenoma occurrence/
recurrence and survival/mortality. Information on mortal-
ity/survival is gathered from linkage with the Municipal
Personal Records Database (in Dutch: Basisregistratie
personen), information on cause of death is ascertained
by linkage with Statistics Netherlands.
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Assessment of quality of life
Quality of life is assessed with the European Organization
for Research and Treatment of Cancer Quality of Life
Questionnaire C30 version 3.0 (EORTC QLQ-C30), which
is a widely used measure of Health-Related Quality of Life
in cancer [46,47]. The questionnaire contains five func-
tioning scales (physical, role, cognitive, emotional, and
social functioning); three symptom scales (fatigue, pain,
and nausea and vomiting); and a global health and
health related quality of life scale. Patient-reported
chemotherapy-induced peripheral neuropathy is assessed
in patients treated with chemotherapy using the “Quality
of Life Questionnaire-CIPN twenty-item scale” (QLQ-
CIPN20); this questionnaire is provided at the 1 year time-
point [48,49]. This 20 item questionnaire includes three
scales assessing sensory, motor and autonomic symptoms
that can result from neuropathy.
An individual’s coping style is assessed with the “Coping
Inventory for Stressful Situations”-CISS questionnaire
[50], a valid and reliable tool to assess basic coping styles.
This inventory measures three different coping styles:
task-oriented, emotion-oriented and avoidance-oriented
coping. Coping style is only assessed at the 2 year time-
point, as this is considered to be a stable factor that will
not change over time.
Power considerations and data analysis
A prospective cohort study assesses multiple exposures
and outcomes. The power calculation for this cohort
study was based on one exposure that was of special
interest in this study – dietary supplement use - and the
anticipated association with recurrence of colorectal
cancer and survival. There are few publications on the
prevalence of dietary supplement use in the general
population in the Netherlands, or among colorectal cancer
patients; therefore, we assume that supplement use in
patients is comparable to supplement use in the general
elderly population: ~45% [51].
Our aim is to include at least 1,000 patients in our
study. After 5 years of follow-up, we expect a number of
320 recurrences and 250 deaths [8,52]. This will enable
us to detect the following associations: for recurrences, a
HR of ≤0.78 or ≥1.31 (alpha = 0.05 and power = 0.8), for
mortality, a HR of ≤0.77 or ≥1.33 (alpha = 0.05 and
power = 0.8).
Cox proportional hazard models will be used to calcu-
late hazard ratios for dietary and lifestyle factors at diag-
nosis in relation to outcomes. Changes of dietary and
lifestyle factors over time will be analyzed with analysis
techniques for longitudinal data, since the observations
of one individual over time are not independent.
All associations will be adjusted for age and sex and
if applicable for stage of the disease. Additionally, we
will check whether other additional variables should be
included in the multivariate models as potential con-
founding variables and/or effect measure modifiers.
Discussion
This is the largest prospective European study among
colorectal cancer patients with repeated information on
a variety of lifestyle factors and other exposures. Recruit-
ment is expected to be complete by the beginning of
2015. This prospective cohort study will shed further
light on the associations between diet, other lifestyle fac-
tors and quality of life, recurrence and survival among
colorectal cancer patients.
Although this is the largest European prospective study
so far, even larger studies are necessary for specific ana-
lyses in subgroups of patients, e.g. within stages of disease,
or within groups of patients with the same treatment.
Therefore, we have harmonised our study protocol with
two other ongoing prospective studies among colorectal
cancer patients: the EnCoRe study of Maastricht Univer-
sity, the Netherlands [53] and with the ColoCare Study of
the German Cancer Research Center in Heidelberg [54].
Thus, in future collaborations, we can pool the results
of these studies to be able to increase the power; the
expected number of patients in all three cohorts will be
at least 2,200.
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